# HeMemics Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hememics-biotechnologies

- Industry: Medical Devices & Equipment
- Headquarters: Gaithersburg, US
- Website: www.hememics.com
- Total disclosed funding: $2.5M
- Latest round: Seed (Dec 11, 2019)
- Investors on record: 1

## About

HeMemics Biotechnologies, Inc. is a US-based company specializing in advanced graphene-based biosensors for rapid detection in biodefense, agriculture, and healthcare diagnostics.HeMemics Biotechnologies, Inc. focuses on the development of innovative biosensor technologies for various applications. Founded in 2019 in Gaithersburg, US, by David Ho, John Warden, and Stephen Bruttig, the company has completed 3 funding deals. Their latest funding round occurred on March 19, 2025, where they raised USD 250,000 from Maryland Technology Development Corporation. This amount reflects the total capital raised by the company to date.HeMemics Biotechnologies, Inc. specializes in advanced graphene-based biosensors designed for rapid and accurate detection across various applications, including biodefense, agriculture, drug testing, and healthcare diagnostics. Their core products, the HemBox™ and HemChip® Reader Biochip, enable users to conduct on-field testing for biotoxins, herbicides, and drugs of abuse, providing actionable results from a single sample in a matter of minutes. The technology primarily serves military personnel, agricultural professionals, healthcare providers, and individuals undergoing drug testing, ensuring that end-users receive reliable and timely data. The company’s products are marketed in various geographical regions, including North America and Europe, focusing on addressing critical needs in public health and safety.HeMemics Biotechnologies generates revenue through direct sales of its biosensor products, including flagship offerings such as the HemBox™ and HemChip® Reader Biochip. The company operates on a business-to-business (B2B) model, engaging with governmental agencies, military organizations, agricultural sectors, and healthcare facilities to provide its solutions. Transactions are structured as direct sales agreements, where clients purchase these devices for their operational needs, ensuring a continuous revenue stream from both initial sales and potential follow-up purchases for consumables or additional units. Pricing details for individual products are set based on the specific applications and volume of sales, catering to both large-scale users and smaller entities within the industries they serve.In March 2025, HeMemics Biotechnologies, Inc. raised USD 250,000 in venture funding from returning investor Maryland Technology Development Corporation. The company will utilize this funding to support its growth and development efforts. Plans for future growth include the design and launch of new products, which are expected to enhance their existing biosensor technology. Additionally, HeMemics aims to expand its market presence in new geographic regions, with a particular focus on increasing sales in Europe and Asia by the end of 2025.

## Funding rounds

- Seed, Dec 11, 2019, $2.5M — AMVI Partners

## Investors

- AMVI Partners (https://capitalatlas.ai/funds/amvi-partners) — Seed